Elan, Ireland’s biggest drug company, has hired investment bankers to carry out a strategic review of its development and manufacturing division, which could see the business floated or sold with a price tag of up to $1.5bn (£755m).

Lehman Brothers and Goldman Sachs are preparing Elan Drug Technology for a listing in London and Dublin, as well as a possible sale to private equity.